Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05070247 · OUTCOME

Dose Escalation: Overall Response Rate (ORR)

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors · Source last updated 2026-01-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
Not reported
Time frame
Up to approximately 32.8 months

What was measured

ORR is defined as the percentage of participants who achieve cPR or cCR (determined by the investigator) during the study in the response-evaluable population. ORR will be assessed as per RECIST Version 1.1. CR: defined as disappearance of all target and non- target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than \<10 mm. PR: defined as at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters. cPR or cCR is defined as a PR or CR that is confirmed with additional imaging 6 weeks after initial response.

Analysis population: The response-evaluable analysis set, a subset of the safety analysis set, included participants with measurable disease at baseline and at least 1 posttreatment tumor evaluation.

Groups in this outcome

Single Agent Dose Escalation: TAK-500 8 µg/kg

Participants received TAK-500, 8 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle (once every 3 weeks, Q3W) for up to 1 year.

Single Agent Dose Escalation: 1 TOCI + TAK-500 8 µg/kg

Participants received premedication with 8 mg/kg (maximum of 800 mg in a single dose) tocilizumab (TOCI) followed by TAK-500, 8 µg/kg IV infusion, once on Day 1 of each 21-day treatment cycle (Q3W) for up to 1 year.

Single Agent Dose Escalation: TAK-500 16 µg/kg

Participants received TAK-500, 16 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle (Q3W) for up to 1 year.

Single Agent Dose Escalation: 1 DEX + TAK-500 16 µg/kg

Participants received premedication with dexamethasone (DEX) as a single 10 mg IV bolus 1 hour before the administration of TAK-500, 16 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle (Q3W) for up to 1 year.

Single Agent Dose Escalation: 2 DEX + TAK-500 16 µg/kg

Participants received premedication with dexamethasone 10 mg orally 12 hours prior and 10 mg IV bolus 1 hour before administration of TAK-500, 16 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle (Q3W) for up to 1 year.

Single Agent Dose Escalation: 1 TOCI + TAK-500 16 µg/kg

Participants received premedication with 8 mg/kg (maximum of 800 mg in a single dose) tocilizumab followed by TAK-500, 16 µg/kg, IV infusion, intravenously, once on Day 1 of each 21-day treatment cycle, Q3W, for up to 1 year.

Single Agent Dose Escalation: 2 DEX + TAK-500 24 µg/kg

Participants received premedication with dexamethasone 10 mg orally 12 hours prior and 10 mg IV bolus 1 hour before administration of TAK-500, 24 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle, Q3W, for up to 1 year.

Single Agent Dose Escalation: 1 TOCI + TAK-500 24 µg/kg

Participants received premedication with 8 mg/kg (maximum of 800 mg in a single dose) tocilizumab followed by TAK-500, 24 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle, Q3W, for up to 1 year.

Single Agent Dose Escalation: 2 DEX + TAK-500 40 µg/kg

Participants received premedication with dexamethasone 10 mg orally 12 hours prior and 10 mg IV bolus 1 hour before administration of TAK-500, 40 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle, Q3W, for up to 1 year.

Single Agent Dose Escalation: 2 DEX + TAK-500 60 µg/kg

Participants received premedication with dexamethasone 10 mg orally 12 hours prior and 10 mg IV bolus 1 hour before administration of TAK-500, 60 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle, Q3W, for up to 1 year.

Combination Dose Escalation: 1 TOCI + Pembrolizumab + TAK-500 8 µg/kg

Participants received premedication with 8 mg/kg (maximum of 800 mg in a single dose) tocilizumab followed by pembrolizumab 200 mg IV infusion, once on Day 1 of each 21-day treatment cycle or on Days 1 and 22 in a 42-day cycle (Q3W) for up to 1 year, along with TAK-500, 8 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle Q3W, for up to 1 year.

Combination Dose Escalation: 1 TOCI + Pembrolizumab + TAK-500 16 µg/kg

Participants received premedication with 8 mg/kg (maximum of 800 mg in a single dose) tocilizumab followed by pembrolizumab 200 mg IV infusion, once on Day 1 of each 21-day treatment cycle, Q3W, for up to 1 year, along with TAK-500, 16 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle Q3W, for up to 1 year.

Combination Dose Escalation: 2 DEX + Pembrolizumab + TAK 500 24 µg/kg

Participants received premedication with dexamethasone 10 mg orally 12 hours prior and 10 mg IV bolus 1 hour before administration of pembrolizumab 200 mg IV infusion, once on Day 1 of each 21-day treatment cycle, Q3W, for up to 1 year, along with TAK-500, 24 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle, Q3W, for up to 1 year.

Combination Dose Escalation: 2 DEX + Pembrolizumab + TAK-500 40 µg/kg

Participants received premedication with dexamethasone 10 mg orally 12 hours prior and 10 mg IV bolus 1 hour before administration of pembrolizumab 200 mg IV infusion, once on Day 1 of each 21-day treatment cycle, Q3W, for up to 1 year, along with TAK-500, 40 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle, Q3W, for up to 1 year.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Single Agent Dose Escalation: TAK-500 8 µg/kg3
Single Agent Dose Escalation: 1 TOCI + TAK-500 8 µg/kg2
Single Agent Dose Escalation: TAK-500 16 µg/kg4
Single Agent Dose Escalation: 1 DEX + TAK-500 16 µg/kg2
Single Agent Dose Escalation: 2 DEX + TAK-500 16 µg/kg3
Single Agent Dose Escalation: 1 TOCI + TAK-500 16 µg/kg4
Single Agent Dose Escalation: 2 DEX + TAK-500 24 µg/kg3
Single Agent Dose Escalation: 1 TOCI + TAK-500 24 µg/kg0
Single Agent Dose Escalation: 2 DEX + TAK-500 40 µg/kg6
Single Agent Dose Escalation: 2 DEX + TAK-500 60 µg/kg2
Combination Dose Escalation: 1 TOCI + Pembrolizumab + TAK-500 8 µg/kg4
Combination Dose Escalation: 1 TOCI + Pembrolizumab + TAK-500 16 µg/kg4
Combination Dose Escalation: 2 DEX + Pembrolizumab + TAK 500 24 µg/kg5
Combination Dose Escalation: 2 DEX + Pembrolizumab + TAK-500 40 µg/kg2

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Single Agent Dose Escalation: TAK-500 8 µg/kg0Not reportedNot reportedNot reportedNot reported
Single Agent Dose Escalation: 1 TOCI + TAK-500 8 µg/kg0Not reportedNot reportedNot reportedNot reported
Single Agent Dose Escalation: TAK-500 16 µg/kg0Not reportedNot reportedNot reportedNot reported
Single Agent Dose Escalation: 1 DEX + TAK-500 16 µg/kg0Not reportedNot reportedNot reportedNot reported
Single Agent Dose Escalation: 2 DEX + TAK-500 16 µg/kg0Not reportedNot reportedNot reportedNot reported
Single Agent Dose Escalation: 1 TOCI + TAK-500 16 µg/kg0Not reportedNot reportedNot reportedNot reported
Single Agent Dose Escalation: 2 DEX + TAK-500 24 µg/kg0Not reportedNot reportedNot reportedNot reported
Single Agent Dose Escalation: 2 DEX + TAK-500 40 µg/kg0Not reportedNot reportedNot reportedNot reported
Single Agent Dose Escalation: 2 DEX + TAK-500 60 µg/kg0Not reportedNot reportedNot reportedNot reported
Combination Dose Escalation: 1 TOCI + Pembrolizumab + TAK-500 8 µg/kg0Not reportedNot reportedNot reportedNot reported
Combination Dose Escalation: 1 TOCI + Pembrolizumab + TAK-500 16 µg/kg0Not reportedNot reportedNot reportedNot reported
Combination Dose Escalation: 2 DEX + Pembrolizumab + TAK 500 24 µg/kg0Not reportedNot reportedNot reportedNot reported
Combination Dose Escalation: 2 DEX + Pembrolizumab + TAK-500 40 µg/kg0Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        0
      3. group Id
        OG002
        value
        0
      4. group Id
        OG003
        value
        0
      5. group Id
        OG004
        value
        0
      6. group Id
        OG005
        value
        0
      7. group Id
        OG006
        value
        0
      8. group Id
        OG008
        value
        0
      9. group Id
        OG009
        value
        0
      10. group Id
        OG010
        value
        0
      11. group Id
        OG011
        value
        0
      12. group Id
        OG012
        value
        0
denoms
  1. counts
    1. group Id
      OG000
      value
      3
    2. group Id
      OG001
      value
      2
    3. group Id
      OG002
      value
      4
    4. group Id
      OG003
      value
      2
    5. group Id
      OG004
      value
      3
    6. group Id
      OG005
      value
      4
    7. group Id
      OG006
      value
      3
    8. group Id
      OG007
      value
      0
    9. group Id
      OG008
      value
      6
    10. group Id
      OG009
      value
      2
    11. group Id
      OG010
      value
      4
    12. group Id
      OG011
      value
      4
    units
    Participants
description
ORR is defined as the percentage of participants who achieve cPR or cCR (determined by the investigator) during the study in the response-evaluable population. ORR will be assessed as per RECIST Version 1.1. CR: defined as disappearance of all target and non- target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than \<10 mm. PR: defined as at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters. cPR or cCR is defined as a PR or CR that is confirmed with additional imaging 6 weeks after initial response.
groups
  1. description
    Participants received TAK-500, 8 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle (once every 3 weeks, Q3W) for up to 1 year.
    id
    OG000
    title
    Single Agent Dose Escalation: TAK-500 8 µg/kg
  2. description
    Participants received premedication with 8 mg/kg (maximum of 800 mg in a single dose) tocilizumab (TOCI) followed by TAK-500, 8 µg/kg IV infusion, once on Day 1 of each 21-day treatment cycle (Q3W) for up to 1 year.
    id
    OG001
    title
    Single Agent Dose Escalation: 1 TOCI + TAK-500 8 µg/kg
  3. description
    Participants received TAK-500, 16 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle (Q3W) for up to 1 year.
    id
    OG002
    title
    Single Agent Dose Escalation: TAK-500 16 µg/kg
  4. description
    Participants received premedication with dexamethasone (DEX) as a single 10 mg IV bolus 1 hour before the administration of TAK-500, 16 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle (Q3W) for up to 1 year.
    id
    OG003
    title
    Single Agent Dose Escalation: 1 DEX + TAK-500 16 µg/kg
  5. description
    Participants received premedication with dexamethasone 10 mg orally 12 hours prior and 10 mg IV bolus 1 hour before administration of TAK-500, 16 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle (Q3W) for up to 1 year.
    id
    OG004
    title
    Single Agent Dose Escalation: 2 DEX + TAK-500 16 µg/kg
  6. description
    Participants received premedication with 8 mg/kg (maximum of 800 mg in a single dose) tocilizumab followed by TAK-500, 16 µg/kg, IV infusion, intravenously, once on Day 1 of each 21-day treatment cycle, Q3W, for up to 1 year.
    id
    OG005
    title
    Single Agent Dose Escalation: 1 TOCI + TAK-500 16 µg/kg
  7. description
    Participants received premedication with dexamethasone 10 mg orally 12 hours prior and 10 mg IV bolus 1 hour before administration of TAK-500, 24 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle, Q3W, for up to 1 year.
    id
    OG006
    title
    Single Agent Dose Escalation: 2 DEX + TAK-500 24 µg/kg
  8. description
    Participants received premedication with 8 mg/kg (maximum of 800 mg in a single dose) tocilizumab followed by TAK-500, 24 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle, Q3W, for up to 1 year.
    id
    OG007
    title
    Single Agent Dose Escalation: 1 TOCI + TAK-500 24 µg/kg
  9. description
    Participants received premedication with dexamethasone 10 mg orally 12 hours prior and 10 mg IV bolus 1 hour before administration of TAK-500, 40 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle, Q3W, for up to 1 year.
    id
    OG008
    title
    Single Agent Dose Escalation: 2 DEX + TAK-500 40 µg/kg
  10. description
    Participants received premedication with dexamethasone 10 mg orally 12 hours prior and 10 mg IV bolus 1 hour before administration of TAK-500, 60 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle, Q3W, for up to 1 year.
    id
    OG009
    title
    Single Agent Dose Escalation: 2 DEX + TAK-500 60 µg/kg
  11. description
    Participants received premedication with 8 mg/kg (maximum of 800 mg in a single dose) tocilizumab followed by pembrolizumab 200 mg IV infusion, once on Day 1 of each 21-day treatment cycle or on Days 1 and 22 in a 42-day cycle (Q3W) for up to 1 year, along with TAK-500, 8 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle Q3W, for up to 1 year.
    id
    OG010
    title
    Combination Dose Escalation: 1 TOCI + Pembrolizumab + TAK-500 8 µg/kg
  12. description
    Participants received premedication with 8 mg/kg (maximum of 800 mg in a single dose) tocilizumab followed by pembrolizumab 200 mg IV infusion, once on Day 1 of each 21-day treatment cycle, Q3W, for up to 1 year, along with TAK-500, 16 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle Q3W, for up to 1 year.
    id
    OG011
    title
    Combination Dose Escalation: 1 TOCI + Pembrolizumab + TAK-500 16 µg/kg
param Type
NUMBER
population Description
The response-evaluable analysis set, a subset of the safety analysis set, included participants with measurable disease at baseline and at least 1 posttreatment tumor evaluation.
reporting Status
POSTED
time Frame
Up to approximately 32.8 months
title
Dose Escalation: Overall Response Rate (ORR)
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice